Cargando…

Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone

INTRODUCTION: Twenty-five percent of stage II colon cancer (CC) patients relapse within 5 years due to minimal residual disease (MRD) not eliminated by surgery. We hypothesise that subtypes of MRD, defined by circulating tumour cells (CTCs) and bone marrow micrometastasis (mM), have different types...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murray, Nigel P, Aedo, Socrates, Villalon, Ricardo, Albarran, Vidal, Orrego, Shenda, Guzman, Eghon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cancer Intelligence 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652547/ https://www.ncbi.nlm.nih.gov/pubmed/33209110 http://dx.doi.org/10.3332/ecancer.2020.1119

Ejemplares similares

Immune Dysfunction as Measured by the Systemic Immune-Inflammation Index is Associated with the Sub-Type of Minimal Residual Disease and Outcome in Stage II Colon Cancer Treated with Surgery alone
por: Murray, Nigel P, et al.
Publicado: (2021)

Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse
por: Murray, Nigel P, et al.
Publicado: (2019)

The CAPRA-S score versus subtypes of minimal residual disease to predict biochemical failure after radical prostatectomy
por: Murray, Nigel P, et al.
Publicado: (2020)

The CAPRA score versus sub-types of minimal residual disease to predict biochemical failure after external beam radiotherapy
por: Murray, Nigel P, et al.
Publicado: (2020)

Subtypes of minimal residual disease, association with Gleason score, risk and time to biochemical failure in pT2 prostate cancer treated with radical prostatectomy
por: Murray, Nigel P, et al.
Publicado: (2019)

Improvement in the Neutrophil-Lymphocyte Ratio after Combined Fluorouracil, Leucovorina and Oxaliplatino based (FOLFOX) Chemotherapy for Stage III Colon Cancer is Associated with Improved Minimal Residual Disease and Outcome
por: Murray, Nigel P, et al.
Publicado: (2022)

Management of mild congenital deficiency of Factor XI with a Factor XI inhibitor in pregnancy: A clinical case
por: Murray, Nigel P., et al.
Publicado: (2022)

Predictive Value of Neutrophil to Lymphocyte Ratio in the Diagnosis of Significant Prostate Cancer at Initial Biopsy: A Comparison with Free Percent Prostate Specific Antigen, Prostate Specific Antigen Density and Primary Circulating Prostate Cells
por: Murray, Nigel P, et al.
Publicado: (2019)

Minimum Residual Disease in Patients Post Radical Prostatectomy for Prostate Cancer: Theoretical Considerations, Clinical Implications and Treatment Outcome
por: Murray, Nigel P, et al.
Publicado: (2018)

Pregnancy in a 31-year-old woman with chronic lymphocytic leukemia: a case report and review of the literature
por: Murray, Nigel P., et al.
Publicado: (2021)

Transient acquired factor XII deficiency associated with moderately severe Covid-19 pneumonia
por: Murray, Nigel P., et al.
Publicado: (2021)

Common B-cell acute lymphoblastic leukaemia in a 70-year-old woman presenting 2 years after carboplatin-taxane radiotherapy for endometrial cancer
por: Murray, Nigel P, et al.
Publicado: (2019)

10 Year Biochemical Failure Free Survival of Men with CD82 Positive Primary Circulating Prostate Cells Treated by Radical Prostatectomy
por: Murray, Nigel P, et al.
Publicado: (2018)

Outcome of radical prostatectomy in primary circulating prostate cell negative prostate cancer
por: Murray, Nigel P, et al.
Publicado: (2016)

The presence of primary circulating prostate cells is associated with upgrading and upstaging in patients eligible for active surveillance
por: Murray, Nigel P, et al.
Publicado: (2017)

Combining the Prostate Cancer Risk Index (PRIX) with the Presence of Secondary Circulating Prostate Cells to Predict the Risk of Biochemical Failure after Radical Prostatectomy for Prostate Cancer
por: Murray, Nigel P, et al.
Publicado: (2018)

Increasing Immune Dysfunction is Associated with Increasing Matrix-Metalloproteinase-2 Expression and Predicts Biochemical Failure in Men with Bone Marrow Micro-Metastasis Positive Localized Prostate Cancer
por: Murray, Nigel P, et al.
Publicado: (2022)

Treatment of Minimal Residual Disease in Breast Cancer: A Longitudinal Case Study
por: Murray, Nigel P
Publicado: (2017)

The presence of secondary circulating prostate tumour cells determines the risk of biochemical relapse for patients with low- and intermediate-risk prostate cancer who are treated only with external radiotherapy
por: Murray, Nigel P, et al.
Publicado: (2018)

Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management
por: Murray, Nigel P.
Publicado: (2018)

Transcriptome Analysis of Minimal Residual Disease in Subtypes of Pediatric B Cell Acute Lymphoblastic Leukemia
por: Sitthi-amorn, Jitsuda, et al.
Publicado: (2015)

Minimally invasive surgery alone compared with intensity-modulated radiotherapy for primary stage I nasopharyngeal carcinoma
por: Liu, You-Ping, et al.
Publicado: (2019)

Clinical implication of minimal presence of solid or micropapillary subtype in early‐stage lung adenocarcinoma
por: Choi, Sun Ha, et al.
Publicado: (2020)

Diabetes alone should not be a reason for withholding adjuvant chemotherapy for stage III colon cancer
por: van Waalwijk, Maren A., et al.
Publicado: (2011)

Clinical Impact of Minimal Residual Disease in Children with Different Subtypes of Acute Lymphoblastic Leukemia Treated with Response-Adapted Therapy
por: Pui, Ching-Hon, et al.
Publicado: (2016)

Diuron, hexazinone, and sulfometuron-methyl applied alone and in mixture in soils: Distribution of extractable residue, bound residue, biodegradation, and mineralization
por: Cristina dos Reis, Fabricia, et al.
Publicado: (2023)

Retrospective Evaluation of Neuropathologic Proxies of the Minimal Atrophy Subtype Compared With Corticolimbic Alzheimer Disease Subtypes
por: Boon, Baayla D.C., et al.
Publicado: (2023)

Minimal residual disease in pediatric ALL
por: Pui, Ching-Hon, et al.
Publicado: (2017)

Minimal Residual Disease, Metastasis and Immunity
por: Badia-Ramentol, Jordi, et al.
Publicado: (2021)

Methods to detect minimal residual disease
por: Haferlach, Torsten
Publicado: (2018)

Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological Malignancies
por: Sánchez, Ricardo, et al.
Publicado: (2019)

Challenges and solutions in patient treatment strategies for stage II colon cancer
por: Fotheringham, Susan, et al.
Publicado: (2019)

Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology)
por: Kim, S Rim, et al.
Publicado: (2018)

Neoadjuvant chemoradiation compared to neoadjuvant radiation alone and surgery alone for Stage II and III soft tissue sarcoma of the extremities
por: Curtis, Kelly K, et al.
Publicado: (2011)

The ctDNA-based postoperative molecular residual disease status in different subtypes of early-stage breast cancer
por: Yang, Yang, et al.
Publicado: (2022)

On the way to specifically targeting minimal residual disease?
por: Gebauer, Gerhard
Publicado: (2008)

Assessment of Minimal Residual Disease in Ewing Sarcoma
por: Wagner, Lars M., et al.
Publicado: (2012)

Dynamics of Minimal Residual Disease in Neuroblastoma Patients
por: Uemura, Suguru, et al.
Publicado: (2019)

The Role and Impact of Minimal Residual Disease in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2021)

The effects of chemotherapy, primary tumor location and histological subtype on the survival of stage III colon cancer patients
por: Zhou, Chenghui, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q7ijmqquvqh8e0d24bjb7kjvvr